Association Between Waste-Free Formularies and Prescription Drug Spending Among Self-insured Employers.
- Published in:
- JAMA Network Open, 2021, v. 4, n. 10, p. e2131486, doi. 10.1001/jamanetworkopen.2021.31486
- By:
- Publication type:
- Article
Works matching AU Socal, Mariana P.
Results: 47
1
2
Factors Associated With Prescriptions for Branded Medications in the Medicare Part D Program.
- Published in:
- JAMA Network Open, 2021, v. 4, n. 3, p. e210483, doi. 10.1001/jamanetworkopen.2021.0483
- By:
- Publication type:
- Article
3
INNOVATION IN THE UNITED STATES HEALTH-CARE SYSTEM'S ORGANIZATION AND DELIVERY.
- Published in:
- School of Public Policy Publications, 2022, v. 15, n. 2, p. 1
- By:
- Publication type:
- Article
4
Right-to-Medicines Litigation and Universal Health Coverage: Institutional Determinants of the Judicialization of Health in Brazil.
- Published in:
- Health & Human Rights: An International Journal, 2020, v. 22, n. 1, p. 221
- By:
- Publication type:
- Article
5
On the Heterogeneity and Politics of the Judicialization of Health in Brazil.
- Published in:
- 2016
- By:
- Publication type:
- Letter to the Editor
6
The Judicialization of Health and the Quest for State Accountability: Evidence from 1,262 Lawsuits for Access to Medicines in Southern Brazil.
- Published in:
- Health & Human Rights: An International Journal, 2016, v. 18, n. 1, p. 209
- By:
- Publication type:
- Article
7
Between the court and the clinic: Lawsuits for medicines and the right to health in Brazil.
- Published in:
- Health & Human Rights: An International Journal, 2012, v. 14, n. 1, p. 1
- By:
- Publication type:
- Article
8
Insulins and the Evolving Landscape of U.S. Prescription Drug Pricing.
- Published in:
- Annals of Internal Medicine, 2023, v. 176, n. 9, p. 1259, doi. 10.7326/M23-1105
- By:
- Publication type:
- Article
9
When States Step Up: California and the Case for State-Led Insulin Manufacturing.
- Published in:
- Annals of Internal Medicine, 2022, v. 175, n. 12, p. 1756, doi. 10.7326/M22-2339
- By:
- Publication type:
- Article
10
Manufacturer-Sponsored Cost-Sharing Programs for Insulin: Are Patients Getting the Help They Need?
- Published in:
- 2022
- By:
- Publication type:
- Letter
11
Off-Label Coverage of High-Cost Drugs by Independent Charity Patient Assistance Programs.
- Published in:
- 2021
- By:
- Publication type:
- Letter
12
Parkinson's disease-associated dyskinesia in countries with low access to levodopa-sparing regimens.
- Published in:
- 2019
- By:
- Publication type:
- Letter
13
Estimating Savings Opportunities From Therapeutic Substitutions of High-Cost Generic Medications.
- Published in:
- JAMA Network Open, 2022, v. 5, n. 11, p. e2239868, doi. 10.1001/jamanetworkopen.2022.39868
- By:
- Publication type:
- Article
14
Measuring and Mitigating Gender-Based Disparities in Earning Potential in Academic Medicine.
- Published in:
- 2022
- By:
- Publication type:
- Opinion
15
Ownership and Interoperability Challenges of Alzheimer Monoclonal Antibody Registries.
- Published in:
- 2024
- By:
- Publication type:
- Opinion
16
Bipartisan Federal Legislation to Address Insulin Access and Affordability.
- Published in:
- Diabetes Spectrum, 2021, v. 34, n. 4, p. 394, doi. 10.2337/ds21-0008
- By:
- Publication type:
- Article
17
Naming Convention, Interchangeability, and Patient Interest in Biosimilars.
- Published in:
- Diabetes Spectrum, 2020, v. 33, n. 3, p. 273, doi. 10.2337/ds19-0065
- By:
- Publication type:
- Article
18
Variability of COPD Inhaler Coverage in Medicare Part D.
- Published in:
- American Journal of Managed Care, 2021, v. 27, n. 5, p. 187, doi. 10.37765/ajmc.2021.88632
- By:
- Publication type:
- Article
19
Biosimilar formulary placement in Medicare Part D prescription drug plans: A case study of infliximab.
- Published in:
- American Journal of Health-System Pharmacy, 2021, v. 78, n. 3, p. 216, doi. 10.1093/ajhp/zxaa376
- By:
- Publication type:
- Article
20
Links Between Chronic Illness and Late-Life Cognition: Evidence From Four Latin American Countries.
- Published in:
- Journal of Aging & Health, 2018, v. 30, n. 2, p. 262, doi. 10.1177/0898264316674557
- By:
- Publication type:
- Article
21
The Pandemic and the Supply Chain: Gaps in Pharmaceutical Production and Distribution.
- Published in:
- 2021
- By:
- Publication type:
- Editorial
22
The Role of Advance Purchasing Commitments in Government Drug Price Negotiations: Lessons From the COVID-19 Response.
- Published in:
- American Journal of Public Health, 2021, v. 111, n. 4, p. 652, doi. 10.2105/AJPH.2020.306109
- By:
- Publication type:
- Article
23
Critical Drugs for Critical Care: Protecting the US Pharmaceutical Supply in a Time of Crisis.
- Published in:
- 2020
- By:
- Publication type:
- Editorial
24
Older Americans' Preferences Between Lower Drug Prices and Prescription Drug Plan Choice, 2019.
- Published in:
- American Journal of Public Health, 2020, v. 110, n. 3, p. 354, doi. 10.2105/AJPH.2019.305483
- By:
- Publication type:
- Article
25
Judicialization 2.0: Understanding right-to-health litigation in real time.
- Published in:
- Global Public Health, 2019, v. 14, n. 2, p. 190, doi. 10.1080/17441692.2018.1474483
- By:
- Publication type:
- Article
26
Strategic Manufacturer Response to the Medicaid Rebate Cap Removal.
- Published in:
- JAMA Health Forum, 2024, v. 5, n. 11, p. e243624, doi. 10.1001/jamahealthforum.2024.3624
- By:
- Publication type:
- Article
27
Dynamics of biological markets with multiple biosimilar competitors in the United States.
- Published in:
- Expert Opinion on Biological Therapy, 2024, v. 24, n. 11, p. 1271, doi. 10.1080/14712598.2024.2412648
- By:
- Publication type:
- Article
28
The CMS Sickle Cell Gene Therapy Access Model.
- Published in:
- 2025
- By:
- Publication type:
- Opinion
29
Drug Shortages—A Study in Complexity.
- Published in:
- 2024
- By:
- Publication type:
- Opinion
30
Clinical Evidence Supporting FDA Approval of Gene and RNA Therapies for Rare Inherited Conditions.
- Published in:
- Pediatric Drugs, 2024, v. 26, n. 6, p. 741, doi. 10.1007/s40272-024-00645-7
- By:
- Publication type:
- Article
31
Reply to Comment on "Market Exclusivity for Drugs with Multiple Orphan Approvals (1983-2017) and Associated Budget Impact in the US".
- Published in:
- 2020
- By:
- Publication type:
- Letter
32
Market Exclusivity for Drugs with Multiple Orphan Approvals (1983-2017) and Associated Budget Impact in the US.
- Published in:
- 2020
- By:
- Publication type:
- journal article
33
Estimation of Tax Benefit of US Nonprofit Hospitals.
- Published in:
- JAMA: Journal of the American Medical Association, 2024, v. 332, n. 20, p. 1732, doi. 10.1001/jama.2024.13413
- By:
- Publication type:
- Article
34
Global Production of Active Pharmaceutical Ingredients for US Generic Drugs Experiencing Shortages.
- Published in:
- JAMA: Journal of the American Medical Association, 2024, v. 331, n. 20, p. 1763, doi. 10.1001/jama.2024.5296
- By:
- Publication type:
- Article
35
Spending on Dual Over-the-Counter and Prescription Drugs in the Medicare Part D Program.
- Published in:
- JAMA: Journal of the American Medical Association, 2024, v. 331, n. 1, p. 72, doi. 10.1001/jama.2023.23126
- By:
- Publication type:
- Article
36
Role of Registries in Medicare Coverage of New Alzheimer Disease Drugs.
- Published in:
- JAMA: Journal of the American Medical Association, 2023, v. 330, n. 14, p. 1331, doi. 10.1001/jama.2023.17131
- By:
- Publication type:
- Article
37
The Price Paradox of Biosimilar-Like Long-Acting Insulin.
- Published in:
- American Journal of Managed Care, 2022, v. 28, n. 11, p. e405, doi. 10.37765/ajmc.2022.89265
- By:
- Publication type:
- Article
38
Occupational pesticide exposure and the risk of death in patients with Parkinson's disease: an observational study in southern Brazil.
- Published in:
- 2020
- By:
- Publication type:
- journal article
39
Reducing Branded Prescription Drug Prices: A Review of Policy Options.
- Published in:
- Pharmacotherapy, 2017, v. 37, n. 11, p. 1469, doi. 10.1002/phar.2013
- By:
- Publication type:
- Article
40
Exploring the Influence of Health Insurance Plans on Biosimilar Adoption Rates.
- Published in:
- PharmacoEconomics - Open, 2024, v. 8, n. 1, p. 115, doi. 10.1007/s41669-023-00447-6
- By:
- Publication type:
- Article
41
Estimating Changes in Medicare Part D and Commercial Insurer Insulin Spending Amid Planned State-Led Biosimilar Insulin Production in California.
- Published in:
- JAMA Internal Medicine, 2023, v. 183, n. 7, p. 734, doi. 10.1001/jamainternmed.2023.0373
- By:
- Publication type:
- Article
42
Changes Associated With the Entry of a Biosimilar in the Insulin Glargine Market.
- Published in:
- 2021
- By:
- Publication type:
- journal article
43
Favorable Formulary Placement of Branded Drugs in Medicare Prescription Drug Plans When Generics Are Available.
- Published in:
- 2019
- By:
- Publication type:
- journal article
44
Consumer Responses to Price Disclosure in Direct-to-Consumer Pharmaceutical Advertising.
- Published in:
- 2019
- By:
- Publication type:
- journal article
45
Trends of Prescription Drug Manufacturer Rebates in Commercial Health Insurance Plans, 2015-2019.
- Published in:
- JAMA Health Forum, 2022, v. 3, n. 5, p. e220888, doi. 10.1001/jamahealthforum.2022.0888
- By:
- Publication type:
- Article
46
Response to Letter to the Editor From Stumpf et al: Cancer Outcomes Among Prediabetes and Type 2 Diabetes Populations With Dietary and Physical Activity-Based Lifestyle Interventions.
- Published in:
- 2023
- By:
- Publication type:
- Letter to the Editor
47
Cancer Outcomes Among Prediabetes and Type 2 Diabetes Populations With Dietary and Physical Activity–based Lifestyle Interventions.
- Published in:
- Journal of Clinical Endocrinology & Metabolism, 2023, v. 108, n. 8, p. 2124, doi. 10.1210/clinem/dgad123
- By:
- Publication type:
- Article